Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 12-2014 | 12-2013 | 12-2012 | 12-2011 | |
| Sales | 23,923,000 | 23,006,000 | 26,505,000 | 26,431,000 | 27,387,000 |
| Cost of Goods | 8,853,000 | 7,323,000 | 8,585,000 | 7,894,000 | 7,332,000 |
| Gross Profit | 15,070,000 | 15,683,000 | 17,920,000 | 18,537,000 | 20,055,000 |
| Operating Expenses | 12,442,000 | 11,377,000 | 12,016,000 | 12,371,000 | 12,835,000 |
| Operating Income | 2,628,000 | 4,306,000 | 5,904,000 | 6,166,000 | 7,220,000 |
| Interest Expense | 735,000 | 703,000 | 740,000 | 760,000 | 799,000 |
| Other Income | 8,633,000 | -635,000 | 1,483,000 | 1,286,000 | 1,277,000 |
| Pre-tax Income | 10,526,000 | 2,968,000 | 6,647,000 | 6,692,000 | 7,698,000 |
| Income Tax | 2,154,000 | 137,000 | 1,019,000 | 1,948,000 | 2,240,000 |
| Net Income Continuous | 8,372,000 | 2,831,000 | 5,628,000 | 4,744,000 | 5,458,000 |
| Minority Interests | 50,000 | -75,000 | -192,000 | -179,000 | -197,000 |
| Net Income | $8,422,000 | $2,756,000 | $5,436,000 | $4,565,000 | $5,261,000 |
| EPS Basic Total Ops | 2.18 | 0.72 | 1.41 | 1.16 | 1.31 |
| EPS Basic Continuous Ops | 2.18 | 0.72 | 1.41 | 1.16 | 1.31 |
| EPS Diluted Total Ops | 2.15 | 0.71 | 1.38 | 1.14 | 1.29 |
| EPS Diluted Continuous Ops | 2.15 | 0.71 | 1.38 | 1.14 | 1.29 |
| EBITDA(a) | $12,891,000 | $5,155,000 | $8,801,000 | $8,897,000 | $9,920,000 |